Supporting the idea that MEOX2 and TWIST1 contribute to oncologic treatment resistance, functional studies have shown that shRNA-mediated TWIST1 silencing in cisplatinum-treated cervical cancer cells regulates the expression of the multi-drug resistance receptor, MDR1/P-gp, also known as ABCB1[33]. Here, TWIST1 is linked to cervical carcinoma.